Pacira BioSciences, Inc. (PCRX) 주식 분석

회사 개요

Pacira BioSciences, Inc. is a specialized healthcare entity focused on the development, manufacture, marketing, and distribution of non-opioid pain management solutions alongside regenerative health products for medical practitioners in the United States. The company operates within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas and specialized pharmaceutical formulations rather than mass-market commodities. As of the latest data, the firm holds a market capitalization of $984.33M and generates annual revenue of $726.41M, supported by an organizational structure comprising 825 employees. These financial dimensions indicate that Pacira maintains a mid-to-large scale position within its niche, possessing sufficient revenue streams to support significant operational activities while maintaining a market valuation that reflects its specialized status in the pain management landscape.

재무 건전성

The company reported total revenue of $726.41M over the trailing twelve months, with a corresponding net income of $7.03M and an EBITDA of $124.33M. The substantial gap between the $726.41M in revenue and the $7.03M in net income reveals a cost structure where operating expenses, likely including high R&D or manufacturing costs inherent to specialty drug production, consume a significant portion of top-line earnings before arriving at the bottom line. Despite the lower net income, the business generated strong free cash flow of $108.56M, which provides substantial financial flexibility for the company to fund operations, invest in research, or manage capital expenditures without immediate external financing. The company operates with a gross margin of 63.2%, indicating strong pricing power and efficient production costs relative to sales, while an operating margin of -1.2% suggests that general and administrative expenses or investment in growth initiatives are currently outpacing operating profits. Furthermore, the profit margin stands at 1.0%, highlighting the challenge of converting total revenue into bottom-line profit in this specific reporting period. On the balance sheet, Pacira holds $238.42M in cash against $418.20M in total debt, resulting in a debt-to-equity ratio of 60.34, which indicates a leveraged balance sheet typical for capital-intensive pharmaceutical firms. However, the current ratio of 4.54 demonstrates a robust short-term liquidity position, ensuring the company can easily meet its obligations due to liquid assets far exceeding current liabilities. Finally, the return on equity is 1.0% and the return on assets is 1.5%, metrics that suggest management is currently deploying capital with modest efficiency, a common trait during phases of heavy investment or market consolidation.

밸류에이션 평가

Pacira BioSciences trades with a trailing P/E ratio of 143.00, which is significantly higher than its forward P/E of 6.55, implying that the market currently prices in substantial future earnings growth that has not yet been realized in recent historical results. The price-to-book ratio is 1.36, indicating that the stock trades at a premium of 36% over its book value, reflecting investor confidence in the company's intangible assets and future pipeline potential beyond its tangible asset base. Alternative valuation metrics such as the price-to-sales ratio of 1.36 and the EV/EBITDA of 8.90 suggest that the company is valued moderately relative to its sales and enterprise value-adjusted earnings, offering a different perspective than the high trailing P/E. The stock has historically fluctuated between a 52-week high of $27.64 and a 52-week low of $18.80, and the current trading price sits at a level that requires specific calculation relative to this range to determine proximity to recent extremes. Additionally, the beta value of 0.23 indicates that the stock exhibits low price volatility relative to the broader market, moving less dramatically than the overall market index during periods of fluctuation.

Growth & Income

The company experienced a revenue growth rate of 5.1% year-over-year, while earnings growth recorded a decline of -88.4% year-over-year, indicating that earnings are growing significantly slower than revenue and reflecting a period where top-line expansion has not yet translated into proportional profit growth. As a non-dividend payer, Pacira reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company does not distribute cash to shareholders and instead retains all earnings to reinvest into growth initiatives such as drug development and market expansion. This strategy aligns with the nature of specialty drug manufacturers that prioritize funding the R&D pipeline over providing current income to investors. Overall, the company presents a growth-oriented profile characterized by steady top-line expansion and a complete reinvestment of cash flows rather than an income-generating dividend strategy.